FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Conway Charles 2. Issuer Name and Ticker or Trading Symbol Biohaven Pharmaceutical Holding Co Ltd. [ BHVN ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Scientific Officer
(Last)         (First)         (Middle)
C/O BIOHAVEN PHARMACEUTICALS, INC., 215 CHURCH STREET
3. Date of Earliest Transaction (MM/DD/YYYY)
11/23/2021
(Street)
NEW HAVEN, CT 06510
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares  11/23/2021    M    10000.00  A $37.54  16012.00  D   
Common Shares  11/23/2021    M    885.00  A $20.79  16897.00  D   
Common Shares  11/25/2021    M    3000.00  A $0.00  19897.00  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)  $37.54  11/23/2021    M        10000.00    (1) 9/4/2027  Common Shares  10000.00  $0.00  0.00  D   
Employee Stock Option (Right to Buy)  $20.79  11/23/2021    M        885.00    (2) 12/6/2027  Common Shares  885.00  $0.00  41727.00  D   
Restricted Share Unit Award   (3) 11/25/2021    M        3000.00    (4)  (5) Common Shares  3000.00  $0.00 (3) 3000.00  D   

Explanation of Responses:
(1)  The shares underlying this option vested in four equal installments on September 5, 2018, 2019, 2020 and 2021.
(2)  The shares underlying this option vest in four equal installments on December 7, 2018, 2019, 2020 and 2021, subject to the reporting person's continued service with the issuer at each vesting date.
(3)  Each restricted share unit represents the contingent right to receive one common share of the issuer.
(4)  The reporting person was granted 12,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date.
(5)  Not applicable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Conway Charles
C/O BIOHAVEN PHARMACEUTICALS, INC.
215 CHURCH STREET
NEW HAVEN, CT 06510


Chief Scientific Officer

Signatures
/s/ Jim Engelhart, Attorney-in-Fact 11/26/2021
**Signature of Reporting Person Date
Biohaven Pharmaceutical (NYSE:BHVN)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Biohaven Pharmaceutical Charts.
Biohaven Pharmaceutical (NYSE:BHVN)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Biohaven Pharmaceutical Charts.